Page 6,692«..1020..6,6916,6926,6936,694..6,7006,710..»

Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The …

Posted: Published on July 10th, 2012

RESEARCH TRIANGLE PARK, N.C., July 9, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the 24th International Congress of the Transplantation Society being held July 15-19th, 2012 at the International Congress Centre Berlin in Berlin, Germany. The poster presentation, entitled "CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK Virus (BKV) Associated Bladder and Kidney End-Organ Damage," is part of the Late Breaking Abstracts session on Monday, July 16th from 12:15-13:30 pm in the Stockholm room. Herve Mommeja-Marin, MD, Vice President of Clinical Research at Chimerix, will present the data from Study 201, Chimerix's Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cells transplant (HSCT) recipients. Phase 2 results presented elsewhere have shown that CMX001, at various doses, was active and well-tolerated in the prevention of CMV infection or disease. This new retrospective analysis focuses on BK virus and shows that CMX001 may prevent end-organ damage in subjects who had BKV infection in the urine upon initiation of therapy. About Chimerix Chimerix is developing novel antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The …

ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

Posted: Published on July 10th, 2012

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the companys three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration (dry AMD). ACT will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), as compared with the 50,000-cell dose used in the first cohort. DSMB authorization to move to the higher dosage of cells in our clinical trial for dry AMD represents a significant milestone for our clinical programs, commented Gary Rabin, chairman and CEO of ACT. Our RPE program is now advancing rapidly, as we are now screening at multiple ophthalmological centers for the fourth surgery in both our dry AMD trial and our U.S. SMD trial, with our E.U. SMD trial, which was initiated much later, not far behind. The trial is a prospective, open-label study, designed to determine … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Posted: Published on July 10th, 2012

Public release date: 6-Jul-2012 [ | E-mail | Share ] Contact: Brianna Deane bdeane@dentistry.ucla.edu 310-206-0835 University of California - Los Angeles The ability to control whether certain stem cells ultimately become bone cells holds great promise for regenerative medicine and potential therapies aimed at treating metabolic bone diseases. Now, UCLA School of Dentistry professor and leading cancer scientist Dr. Cun-Yu Wang and his research team have made a significant breakthrough in that direction. The scientists have discovered two key epigenetic regulating genes that govern the cell-fate determination of human bone marrow stem cells. Wang's new research is featured on the cover of the July 6 issue of Cell Stem Cell, the affiliated journal of the International Society for Stem Cell Research. The groundbreaking study grew out of Wang's desire to better understand the epigenetic regulation of stem cell differentiation, in which the structure of genes is modified while the sequence of the DNA is not. He and his team found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This process occurs through the activation of certain genes favoring a commitment to one lineage and the concurrent … Continue reading →

Comments Off on UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Arthritis stem cell jab 'could ease pain for millions'

Posted: Published on July 10th, 2012

Stem cells taken from stomach fat and used to regenerate knee tissue Charity chief says therapy potentially 'transformational' By Claire Bates PUBLISHED: 05:15 EST, 10 July 2012 | UPDATED: 05:31 EST, 10 July 2012 An injection of stem cells taken from body fat could one day help patients recover from crippling osteoarthritis. The treatment, which has been successfully trialled on animals, helps the body regrow tissue and cartilage that has been damaged by the degenerative condition. Although still at an experimental stage, experts say the therapy could be 'transformational' for the six million people in the UK who suffer from the condition. Osteoarthritis occurs when there is damage in and around a joint which the body cannot repair Early results suggest the treatment, from Australian company Regeneus, could delay the need for joint repair by 10 or 20 years. There is the possibility that it could stop the disease's progression altogether if caught early. Judith Brodie, chief executive of Arthritis Care, told Mail Online: 'This new stem cell therapy, if the trials continue to show success, could be transformational. 'While the long-term effects are unknown, and there should be caution due to the early stage of development, Arthritis Care welcomes … Continue reading →

Comments Off on Arthritis stem cell jab 'could ease pain for millions'

Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

Posted: Published on July 10th, 2012

ScienceDaily (July 9, 2012) The ability to control whether certain stem cells ultimately become bone cells holds great promise for regenerative medicine and potential therapies aimed at treating metabolic bone diseases. Now, UCLA School of Dentistry professor and leading cancer scientist Dr. Cun-Yu Wang and his research team have made a significant breakthrough in that direction. The scientists have discovered two key epigenetic regulating genes that govern the cell-fate determination of human bone marrow stem cells. Wang's new research is featured on the cover of the July 6 issue of Cell Stem Cell, the affiliated journal of the International Society for Stem Cell Research. The groundbreaking study grew out of Wang's desire to better understand the epigenetic regulation of stem cell differentiation, in which the structure of genes is modified while the sequence of the DNA is not. He and his team found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This process occurs through the activation of certain genes favoring a commitment to one lineage and the concurrent deactivation of genes favoring other lineages. The findings imply that chemical manipulation of these gene-activating enzymes may … Continue reading →

Comments Off on Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

Fort Myers doctor reaching settlement with state in stem cell patient's death

Posted: Published on July 10th, 2012

K.K.Yankopolus Photo by Allie Garza Dr. Zannos Grekos, a cardiologist whose practice is in Bonita Springs, speaks with a seminar attendant after one of his educational seminars about stem cell treatment, using one's own stem cells, for treating heart disease and other medical conditions, on Monday, March 14, 2011, at the Collier County Library. Allie Garza/Staff FORT MYERS A Fort Myers physician whose license was restricted for his involvement in a controversial stem cell treatment on a patient who died has a settlement in the works with state regulators. Terms of the deal between Dr. Konstantine Yankopolus and the Florida Department of Health weren't immediately available Monday. "It's in draft form," said Yankopolus' attorney, Steven Ramunni, of Fort Myers. Yankopolus said Monday he expects the restriction on his license to be lifted soon. "I want to stay in the world of service," he said. "Let's move on." An obstetrician for years before switching to a general practice, Yankopolus assisted Dr. Zannos Grekos, a Bonita Springs cardiologist, on March 2 in a stem cell procedure on a 77-year-old Indiana man. The patient, Richard Poling, came to Grekos for stem cell treatment against his pulmonary hypertension. Grekos accepted the patient even though … Continue reading →

Comments Off on Fort Myers doctor reaching settlement with state in stem cell patient's death

Prescription Drugs Are Killing San Diegans

Posted: Published on July 10th, 2012

Prescription drugs are killing more San Diegans than ever before, according to the Countys first Prescription Drug Abuse Report Card released today. The report tracked a five-year period from 2007 to 2011. Last year, prescription drugs played a role in the deaths of 267 people, a 27 percent increase compared to 2007 when 211 deaths were reported. A total of 1,164 people have died due to prescription drugs in the last five years. Prescription drug abuse has become a serious problem in our county. Many young people and adults are abusing prescription drugs. And these drugs can be found at home, said Supervisor Pam Slater-Price at a Monday news conference. The report card, which includes nine indicators of prescription drug abuse in the region, also showed the following trends: Emergency room visits due to opiates were up by 64 percent Total students reporting prescription drug abuse increased (from 17 to 19.6 percent) The number of juveniles and adults reporting prescription drug misuse also increased (from 33 to 37 percent and 40 to 41 percent respectively) Number of robberies/burglaries to pharmacies also rose from 9 to 26 incidents, a whopping 188 percent increase. What the report card shows is alarming, said … Continue reading →

Posted in Drugs | Comments Off on Prescription Drugs Are Killing San Diegans

Law Rewards Drug Companies for Developing Cancer Drugs for Kids

Posted: Published on July 10th, 2012

Jul 9, 2012 9:38pm Image credit: Nancy Goodman/Kids v. Cancer President Obama signed a bill today that will provide incentives to drug companies to research and develop drugs for rare diseases. The Creating Hope Act grants pharmaceutical companies that create drugs for diseases like childhood cancers a voucher giving speedier review of any other drug they submit for approval. The Oval Office signature was a hard-fought victory for children like Mollie Ward, 11, who survived a rare form of pancreatic cancer thanks to an experimental drug, and for other families who have fought childhood cancers. Nancy Goodman, founder of Kids v. Cancer, which is devoted to pediatric cancer research, lost her son Jacob Froman, 10, to a rare form of brain cancer nearly four years ago. Hed been diagnosed at the age of 8. She was instrumental in getting the bill passed. She and others said that drug companies had little financial incentive to develop new treatments because childhood cancers are so rare. The reason I started working on the Creating Hope Act was that I found very early on that there are just very few drugs to treat kids with cancer, she told ABC News. We created a big, … Continue reading →

Posted in Drugs | Comments Off on Law Rewards Drug Companies for Developing Cancer Drugs for Kids

Pharmacy robbed at gunpoint

Posted: Published on July 10th, 2012

Two armed men robbed a northeast Indiana pharmacy before dawn Monday, forcing two employees onto the floor and the other to open the safe before grabbing medications. The Warsaw Police Department is investigating the robbery that happened at the CVS Pharmacy, 100 N. Detroit St., about 4:10 a.m. In a written statement, the department said the men were 20-30 years old and white. One was wearing a full-face red plastic Spider-Man mask with red tightening straps and surgical gloves. The other was wearing a tan safari-type hat or possible straw hat, a blue bandanna covering his face, sunglasses and surgical-type gloves. The employees watched the robbers head to the front door, but they could not get out, so they left out a side emergency exit. Warsaw police brought in a police dog to track the robbers north along the train tracks, but the trail ended near the parking lot south of the Salvation Army on Arthur Street, the statement said. Anyone with information about the robbery is asked to call the Warsaw Police Investigations Division at 574-372-9535 or call Crime Stoppers at 800-342-7867. Continued here: Pharmacy robbed at gunpoint … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy robbed at gunpoint

TiGenix : enrolment first patients in pivotal Phase III trial with lead product Cx601

Posted: Published on July 10th, 2012

Regulated information July 10, 2012 TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas ADMIRE CD trial to enroll over 200 patients in 46 centers across 8 countries Leuven (BELGIUM) - July 10, 2012 - TiGenix (NYSE Euronext: TIG) announced today the enrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn`s disease patients at Hospital Clnic, Barcelona, Spain. Cx601 is an adipose derived allogeneic stem cell therapy. ADMIRE-CD is a multicenter, randomized, double-blind, placebo-controlled Phase III trial of Cx601 in approximately 200 Crohn`s disease patients suffering from complex perianal fistulas. The main objectives of the study are to demonstrate safety and superior efficacy over placebo in perianal fistulas in Crohn`s disease patients after failure with their previous treatment, in most cases biologicals, and to confirm the strong safety and efficacy results from the Phase II trial completed in 2011. To date, the company has already received approvals from Ethical Committees or Regulatory Agencies in 7 out of 8 countries, which should allow the company to accelerate patient enrolment in the study. Dr. Jose Luis Bravo, VP Global Medical Affairs & … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on TiGenix : enrolment first patients in pivotal Phase III trial with lead product Cx601

Page 6,692«..1020..6,6916,6926,6936,694..6,7006,710..»